Mark Jacobson, MD

Professor

Dr. Jacobson is a clinician, educator, and researcher who specialized in HIV/AIDS and its complications after joining the UCSF faculty in 1986. His career began with leading multicenter, interventional trials that focused on developing effective treatments for AIDS-associated opportunistic infections. His subsequent research was translational, investigating protective immunity against chronic viral infections, in particular cytomegalovirus (CMV), HIV, and human papillomavirus (HPV). He taught medicine residents and medical students and provided clinical care in the Ward 86 HIV clinic at San Francisco General Hospital until March, 2020, when he moved to the Occupational Medicine division to become the infectious diseases consultant for a team of MDs, NPs and RNs who created a system to manage employee COVID-19 health issues for health care personnel working at SF General and affiliated SF Department of Public Health facilities. This included a Occupational Health Service COVID-19 Hotline and Hotline staff standard work guidance for testing/off-return to work decisions, vaccination, and management of COVID-19 vaccine adverse events. Dr. Jacobson initiated a quality improvement program that analyzes data collected by the Hotline to address questions regarding optimal employee management policies. His QI efforts have resulted in 4 medical journal publications to date. He continues to teach Hotline staff and Occupational Medicine residents, consult with Occupational Medicine leadership re policy changes and special issues that arise, and mentor junior faculty conducting observational studies of COVID-19 in health care personnel. Dr. Jacobson is also the author of Sensing Light, a novel published in 2016 about the unfolding of the AIDS epidemic in 1980s San Francisco from the perspective of front-line, treating physicians (see http://markajacobsonauthor.com/).
Education
Fellowship, 1986 - Infectious Diseases, University of California, Los Angeles
Internship/Residency, 1984 - Medicine, Kaiser Foundation Hospital, Oakland, CA
M.D., 1981 - Medicine, University of California, San Francisco
Honors and Awards
  • AIDS Research Institute Sarlo Award for Teaching Excellence, UCSF, 2013
  • Positive Health Program Teaching Award, UCSF, 2007
Websites
Publications

  2. Jacobson M, Hart C, Huen W, Suarez Guardado G, Villanueva A, Whitman J, Blanc PD. A Rapid Nucleic-Acid-Amplification-Test-Based, Conditional-Release-to-Work Policy for Health Care Personnel with Symptoms Consistent with COVID-19. 2022. PMID: 36240750


  3. Jacobson MA, Zakaria A, Maung Z, Hart C, McCalmont T, Fassett M, Amerson E. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 SARS-CoV2 Vaccine (Moderna) in a Cohort of Hospital Employees. 2021. PMID: 34086881


  4. Maung Z, Kristensen M, Hoffman B, Jacobson MA. Temperature Screening of Healthcare Personnel is Ineffective in Controlling COVID-19. 2022. PMID: 35166255


  5. Presti RM, Handley SA, Droit L, Ghannoum M, Jacobson M, Shiboski CH, Webster-Cyriaque J, Brown T, Yin MT, Overton ET. Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status. 2018. PMID: 29851662


  6. Shiboski CH, Lee A, Chen H, Webster-Cyriaque J, Seaman T, Landovitz RJ, John M, Reilly N, Naini L, Palefsky J, Jacobson MA. Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy. 2016. PMID: 26919735


  7. Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson CA, Collier AC, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson MA. Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS. 2014. PMID: 24378728


  8. Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Benson C, Keiser P, van der Horst C, Jacobson MA. The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. 2013. PMID: 24260125


  9. Meyer AC, Jacobson M. Asymptomatic cryptococcemia in resource-limited settings. 2013. PMID: 23715897


  10. Jacobson M, Lurain N, Hunt P. Cytomegalovirus viraemia in the modern antiretroviral era(*). Volume 12 of Issue 7. 2011. PMID: 21729228


  11. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. Volume 203 of Issue 10. 2011. PMID: 21502083


  14. Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. 2009. PMID: 19632953


  15. Jacobson MA, Ditmer DP, Sinclair E, Martin JN, Deeks SG, Hunt P, Mocarski ES, Shiboski C. Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients. Volume 4 of Issue 4. 2009. PMID: 19381272


  16. Jacobson MA, Adler SP, Sinclair E, Black D, Smith A, Chu A, Moss RB, Wloch MK. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). 2009. PMID: 19168107


  17. Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. Volume 49 of Issue 2. 2008. PMID: 18820536


  18. Jacobson MA, Tan QX, Girling V, Poon C, Van Natta M, Jabs DA, Inokuma M, Maecker HT, Bredt B, Sinclair E. Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS. 2008. PMID: 18173357


  20. Sinclair E, Tan QX, Sharp M, Girling V, Poon C, Natta MV, Jabs DA, Inokuma M, Maecker HT, Bredt B, Jacobson MA. Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype. 2006. PMID: 17083038


  21. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Girling V, Adler SP. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. 2006. PMID: 16701925


  22. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Adler SP. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. 2006. PMID: 16387547


  23. Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F. Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. 2005. PMID: 16306031


  24. Jabs DA, Holbrook JT, Van Natta ML, Clark R, Jacobson MA, Kempen JH, Murphy RL. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. 2005. PMID: 15878056


  25. Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. 2005. PMID: 16192248


  27. D'Amico R, Yang Y, Mildvan D, Evans SR, Schnizlein-Bick CT, Hafner R, Webb N, Basar M, Zackin R, Jacobson MA. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. 2005. PMID: 15821887


  29. Shacklett BL, Cox CA, Quigley MF, Kreis C, Stollman NH, Jacobson MA, Andersson J, Sandberg JK, Nixon DF. Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection. 2004. PMID: 15210827


  32. Sinclair E, Black D, Epling CL, Carvidi A, Josefowicz SZ, Bredt BM, Jacobson MA. CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals. 2004. PMID: 15357911


  33. Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC, Glesby MJ. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. 2003. PMID: 14673758


  34. Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF. Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection. 2003. PMID: 12719554


  35. Jacobson MA, Liu L, Khayam-Bashi H, Deeks SG, Hecht FM, Kahn J. Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. 2003. PMID: 12660541


  36. Jacobson MA, Khayam-Bashi H, Martin JN, Black D, Ng V. Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. 2002. PMID: 12473834


  39. Nokta MA, Holland F, De Gruttola V, Emery VC, Jacobson MA, Griffiths P, Pollard RB, Feinberg JE. Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease. 2002. PMID: 12085316


  40. Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, Fox L, Roe J, Kundu S, Pollard R. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. 2002. PMID: 12004273


  42. Jacobson MA, Schrier R, McCune JM, Torriani FJ, Holland GN, O'Donnell JJ, Freeman WR, Bredt BM. Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. 2001. PMID: 11294673


  43. Chin-Hong PV, Sutton DA, Roemer M, Jacobson MA, Aberg JA. Invasive fungal sinusitis and meningitis due to Arthrographis kalrae in a patient with AIDS. 2001. PMID: 11158158


  44. Angel JB, Jacobson MA, Skolnik PR, Giordano M, Shapiro L, LeBeaut A, Greaves W, Fuchs AC. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. 2000. PMID: 11101061


  47. Aweeka FT, Jacobson MA, Martin-Munley S, Hedman A, Schoenfeld P, Omachi R, Tsunoda S, Gambertoglio JG. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. 1999. PMID: 10096579


  49. Jacobson MA, Wilson S, Stanley H, Holtzer C, Cherrington J, Safrin S. Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS. 1999. PMID: 10194072


  53. Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, McCune JM. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. 1998. PMID: 9701250


  54. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, Hardy WD, Polis MA, Deutsch TA, Feinberg J, Spector SA, Walmsley S, Drew WL, Powderly WG, Griffiths PD, Benson CA, Kessler HA. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. 1998. PMID: 9588429


  55. Jacobson MA. AIDS-related cytomegalovirus retinitis. 1998. PMID: 15010704


  57. Feinberg JE, Hurwitz S, Cooper D, Sattler FR, MacGregor RR, Powderly W, Holland GN, Griffiths PD, Pollard RB, Youle M, Gill MJ, Holland FJ, Power ME, Owens S, Coakley D, Fry J, Jacobson MA. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study G 1998. PMID: 9419169


  61. Fredricks DN, Rojanasthien N, Jacobson MA. AIDS-related disseminated histoplasmosis in San Francisco, California. 1997. PMID: 9392979


  65. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, Owens S, Pollard R. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. 1997. PMID: 9164318


  66. Mueller AJ, Jacobson MA, Hurwitz S, Chuang EL, Friedberg DN, Haidt SJ, Heinemann MH, Jabs DA, Kaplan HJ, Freeman WR. Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovir. 1997. PMID: 9147441


  68. Marra CM, Gary DW, Kuypers J, Jacobson MA. Diagnosis of neurosyphilis in patients infected with human immunodeficiency virus type 1. 1996. PMID: 8655999


  70. Harb GE, Mandema JW, Delahunty T, Benowitz NB, Coleman R, Sheiner LB, Jacobson MA. Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection. 1996. PMID: 8537676


  72. Jacobson MA, De Gruttola V, Reddy M, Arduino JM, Strickland S, Reichman RC, Bartlett JA, Phair JP, Hirsch MS, Collier AC. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. 1995. PMID: 7546418


  75. Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, Jacobson MA. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. 1995. PMID: 7712668


  77. Flexner C, van der Horst C, Jacobson MA, Powderly W, Duncanson F, Ganes D, Barditch-Crovo PA, Petty BG, Baron PA, Armstrong D. Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. 1994. PMID: 7995977


  80. Jacobson MA, Gallant J, Wang LH, Coakley D, Weller S, Gary D, Squires L, Smiley ML, Blum MR, Feinberg J. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. 1994. PMID: 7979285


  81. Jacobson MA, Kramer F, Bassiakos Y, Hooton T, Polsky B, Geheb H, O'Donnell JJ, Walker JD, Korvick JA, van der Horst C. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. 1994. PMID: 8014496


  82. Jacobson MA, Polsky B, Causey D, Davis R, Tong W, O'Donnell JJ, Kuppermann BD, Heinemann MH, Feinberg J, Lizak P. Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis. 1994. PMID: 8067763


  84. Stanley HD, Charlebois E, Harb G, Jacobson MA. Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease. 1994. PMID: 8106966


  85. Chin DP, Hopewell PC, Yajko DM, Vittinghoff E, Horsburgh CR, Hadley WK, Stone EN, Nassos PS, Ostroff SM, Jacobson MA. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. 1994. PMID: 7906290


  87. Jacobson MA, Causey D, Polsky B, Hardy D, Chown M, Davis R, O'Donnell JJ, Kuppermann BD, Heinemann MH, Holland GN. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. 1993. PMID: 8393058


  90. Jacobson MA, Yajko D, Northfelt D, Charlebois E, Gary D, Brosgart C, Sanders CA, Hadley WK. Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. 1993. PMID: 8515098


  91. Dyner TS, Lang W, Geaga J, Golub A, Stites D, Winger E, Galmarini M, Masterson J, Jacobson MA. An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease. 1993. PMID: 8097787


  94. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. 1992. PMID: 1453334


  95. Reddy MM, Grieco MH, McKinley GF, Causey DM, van der Horst CM, Parenti DM, Hooton TM, Davis RB, Jacobson MA. Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. 1992. PMID: 1323624


  99. Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Deyton L. Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. 1992. PMID: 1346413


  100. Bacchetti P, Moss AR, Andrews JC, Jacobson MA. Early predictors of survival in symptomatic HIV-infected persons treated with high-dose zidovudine. 1992. PMID: 1535375


  101. Jacobson MA. Review of the toxicities of foscarnet. 1992. PMID: 1534839


  103. Jacobson MA, Hopewell PC, Yajko DM, Hadley WK, Lazarus E, Mohanty PK, Modin GW, Feigal DW, Cusick PS, Sande MA. Natural history of disseminated Mycobacterium avium complex infection in AIDS. 1991. PMID: 1682396


  105. Jacobson MA, Mills J, Rush J, Peiperl L, Seru V, Mohanty PK, Hopewell PC, Hadley WK, Broadus VC, Leoung G. Morbidity and mortality of patients with AIDS and first-episode Pneumocystis carinii pneumonia unaffected by concomitant pulmonary cytomegalovirus infection. 1991. PMID: 1648316


  106. Jacobson MA, Drew WL, Feinberg J, O'Donnell JJ, Whitmore PV, Miner RD, Parenti D. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. 1991. PMID: 1645385


  107. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. 1991. PMID: 1827127


  109. Jacobson MA, Bacchetti P, Kolokathis A, Chaisson RE, Szabo S, Polsky B, Valainis GT, Mildvan D, Abrams D, Wilber J. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. 1991. PMID: 1671651


  111. Wilcox CM, Diehl DL, Cello JP, Margaretten W, Jacobson MA. Cytomegalovirus esophagitis in patients with AIDS. A clinical, endoscopic, and pathologic correlation. 1990. PMID: 2169217


  112. Wilcox CM, Byford BA, Forsmark CE, Hadley WK, Cello JP, Jacobson MA. Campylobacter-like organisms are uncommon pathogens in patients infected with the human immunodeficiency virus. 1990. PMID: 2229366


  113. Leoung GS, Feigal DW, Montgomery AB, Corkery K, Wardlaw L, Adams M, Busch D, Gordon S, Jacobson MA, Volberding PA. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. 1990. PMID: 1975426


  114. Farese RV, Schambelan M, Hollander H, Stringari S, Jacobson MA. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. 1990. PMID: 2160217


  115. Jacobson MA, Peiperl L, Volberding PA, Porteous D, Toy PT, Feigal D. Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome. 1990. PMID: 2305441


  118. Jacobson MA, Abrams DI, Volberding PA, Bacchetti P, Wilber J, Chaisson RE, Crowe S, Howard W, Moss A. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. 1989. PMID: 2566637


  122. O'Donnell JJ, Jacobson MA. Cotton-wool spots and cytomegalovirus retinitis in AIDS. 1989. PMID: 2541095


  124. Jacobson MA, McGrath MS, Joseph P, Molaghan JB, Tadepalli S, Quinn R. Zidovudine-induced fever. 1989. PMID: 2666640


  125. Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, McManus N, Mills J. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. 1988. PMID: 2844921


  126. Jacobson MA, Mills J, Rush J, O'Donnell JJ, Miller RG, Greco C, Gonzales MF. Failure of antiviral therapy for acquired immunodeficiency syndrome-related cytomegalovirus myelitis. 1988. PMID: 2845899


  127. Jacobson MA, de Miranda P, Gordon SM, Blum MR, Volberding P, Mills J. Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy. 1988. PMID: 3261316


  129. Jacobson MA, O'Donnell JJ, Brodie HR, Wofsy C, Mills J. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. 1988. PMID: 2844981


  130. Mills J, Jacobson MA, O'Donnell JJ, Cederberg D, Holland GN. Treatment of cytomegalovirus retinitis in patients with AIDS. 1988. PMID: 2847289


  131. Ng VL, Jacobson MA, Khayam-Bashi H, McGrath MS. Lymphoma in an HIV-positive man after disappearance of a paraprotein. 1988. PMID: 3259675


  135. Jacobson MA, de Miranda P, Cederberg DM, Burnette T, Cobb E, Brodie HR, Mills J. Human pharmacokinetics and tolerance of oral ganciclovir. 1987. PMID: 2820301